To avoid jeopardizing CAR‐T cell function, the initial recommendation of steroid use was limited to patients with CRS refractory to anti-IL‐6 therapy or patients with grade 3–4 CRS toxicities [9]. Here, IL6 is linked to congenital rubella syndrome.